The Effect of switch from Febuxostat to Dotinurad on the serum levels of indoxyl sulfate in patients with chronic kidney

The Effect of switch from Febuxostat to Dotinurad on the serum levels of indoxyl sulfate in patients with chronic kidney - The Effect of switch from Febuxostat to Dotinurad on the serum levels of indoxyl sulfate in patients with chronic kidney

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000046180

Enrollment

Registered

2021-11-26

Start date

2022-01-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperuricemia Chronic kidney disease

Interventions

The switch from Febuxostat (20 mg/day) to Dotinurad (1 mg/day) in all the enrolled CKD patients.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) 19<Age<80 2) CKD(StageG3, eGFR30-60ml/min/1.73m2) 3) a patient with hyperuricemia taking oral febuxostat 4) male and female 5) outpatient clinic

Exclusion criteria

Exclusion criteria: 1) severe heart failure (NYHA>2) 2) a patient taking oral statin 3) Liver dysfunction (Child Pugh - Grade B or C) 4) Allergy 5) a patient with chronic inflammatory disease taking NSAIDs, steroid and immunosuppressants. 6) a patient who is considered ineligible for enrolling the study by a principal investigator or sub-investigator

Design outcomes

Primary

Measure	Time frame
Serum indoxyl sulfate level	—

Countries

Japan

Contacts

Public ContactHidekazu Kondo

Oita University Faculty of Medicine

hkondo@oita-u.ac.jp0975866166

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026